CA2928235A1 - Procedes de traitement de dystrophies musculaires - Google Patents

Procedes de traitement de dystrophies musculaires Download PDF

Info

Publication number
CA2928235A1
CA2928235A1 CA2928235A CA2928235A CA2928235A1 CA 2928235 A1 CA2928235 A1 CA 2928235A1 CA 2928235 A CA2928235 A CA 2928235A CA 2928235 A CA2928235 A CA 2928235A CA 2928235 A1 CA2928235 A1 CA 2928235A1
Authority
CA
Canada
Prior art keywords
compound
subject
pharmaceutically acceptable
acceptable salt
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2928235A
Other languages
English (en)
Inventor
Francois Nique
Catherine Jagerschmidt
Florence Sylvie Namour
Jean-Michael LEFRANCOIS
Ernest D. BUSH
Christophe Peixoto
Pierre Deprez
Nicolas Triballeau
Piet Tom Burt Paul Wigerinck
Roland Blanque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2928235A1 publication Critical patent/CA2928235A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne, notamment, le traitement d'une dystrophie musculaire (par exemple, la dystrophie musculaire de Duchenne) au moyen d'une composition, par exemple, une composition comprenant un composé (I) ou un sel pharmaceutiquement acceptable, un promédicament ou son métabolite.
CA2928235A 2013-10-25 2014-10-24 Procedes de traitement de dystrophies musculaires Abandoned CA2928235A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895832P 2013-10-25 2013-10-25
US61/895,832 2013-10-25
PCT/US2014/062178 WO2015061685A1 (fr) 2013-10-25 2014-10-24 Procédés de traitement de dystrophies musculaires

Publications (1)

Publication Number Publication Date
CA2928235A1 true CA2928235A1 (fr) 2015-04-30

Family

ID=52993619

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2928235A Abandoned CA2928235A1 (fr) 2013-10-25 2014-10-24 Procedes de traitement de dystrophies musculaires

Country Status (9)

Country Link
US (2) US20160250188A1 (fr)
EP (1) EP3060206A4 (fr)
JP (1) JP2016538269A (fr)
CN (1) CN105979943A (fr)
AU (1) AU2014339917A1 (fr)
BR (1) BR112016009214A8 (fr)
CA (1) CA2928235A1 (fr)
MX (1) MX2016005287A (fr)
WO (1) WO2015061685A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
EP4066850A3 (fr) * 2017-02-22 2022-11-23 Bioincept LLC Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant
US20210361635A1 (en) * 2018-06-05 2021-11-25 The Regents Of The University Of California Methods for treating muscular dystrophies
CN113924085A (zh) * 2019-04-12 2022-01-11 加利福尼亚大学董事会 用于增加肌肉量和氧化代谢的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715087D0 (en) * 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB2463514C (en) * 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
ITBO20090078A1 (it) * 2009-02-13 2010-08-14 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi

Also Published As

Publication number Publication date
AU2014339917A1 (en) 2016-05-12
EP3060206A1 (fr) 2016-08-31
MX2016005287A (es) 2017-02-22
JP2016538269A (ja) 2016-12-08
WO2015061685A1 (fr) 2015-04-30
BR112016009214A8 (pt) 2020-03-24
EP3060206A4 (fr) 2017-04-19
US20190167640A1 (en) 2019-06-06
CN105979943A (zh) 2016-09-28
US20160250188A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
US20190167640A1 (en) Methods for treatment of muscular dystrophies
US20220072005A1 (en) Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type i muscle fibers in an immobilized limb
CN114929209A (zh) 肌萎缩侧索硬化的治疗
US20240058353A1 (en) Methods for treating gi tract disorders
WO2015127556A1 (fr) Procédés et utilisations pour induire ou faciliter la défécation chez un patient en ayant besoin
US10195165B2 (en) Methods of treating Prader-Willi syndrome
Morrison Dystrophinopathies
CN112654367B (zh) 用于年龄相关性和/或变性疾病的药物组合
WO2020086551A1 (fr) Nouvelle génération de facteurs de transcription synthétiques
US20210323954A1 (en) Novel polymorphic forms of metopimazine
McDonald Neuromuscular diseases
US20240197756A1 (en) Methods of treatment with neuroactive steroids
Maricelli Phenotypic Characterization and Treatment of a Novel Mouse Model for Limb-Girdle Muscular Dystrophy 2i
Syed et al. Muscular Dystrophy: Underlying Cellular and Molecular Mechanisms and Various Nanotherapeutic Approaches for Muscular Dystrophy
Goemans Therapy development and clinical outcome measures for Duchenne muscular dystrophy
WO2024054412A1 (fr) Méthodes et compositions pour le traitement de la sclérose latérale amyotrophique
Cal et al. A Nitroalkene Derivative of Salicylate Alleviates Diet-Induced Obesity by Activation of Creatine-Dependent Thermogenesis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191024

FZDE Discontinued

Effective date: 20220426

FZDE Discontinued

Effective date: 20220426